首页> 美国卫生研究院文献>PLoS Clinical Trials >Fluid balance-adjusted creatinine at initiation of continuous venovenous hemofiltration and mortality. A post-hoc analysis of a multicenter randomized controlled trial.
【2h】

Fluid balance-adjusted creatinine at initiation of continuous venovenous hemofiltration and mortality. A post-hoc analysis of a multicenter randomized controlled trial.

机译:持续静脉静脉血液滤过和死亡开始时,需进行液体平衡调整的肌酐。多中心随机对照试验的事后分析。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionAcute kidney injury (AKI) requiring renal replacement therapy (RRT) is associated with high mortality. The creatinine-based stage of AKI is considered when deciding to start or delay RRT. However, creatinine is not only determined by renal function (excretion), but also by dilution (fluid balance) and creatinine generation (muscle mass). The aim of this study was to explore whether fluid balance-adjusted creatinine at initiation of RRT is related to 28-day mortality independent of other markers of AKI, surrogates of muscle mass and severity of disease.
机译:简介需要肾脏替代疗法(RRT)的急性肾损伤(AKI)与高死亡率相关。在决定开始或延迟RRT时应考虑AKI的基于肌酐的阶段。但是,肌酐不仅取决于肾功能(排泄),还取决于稀释度(流体平衡)和肌酐生成(肌肉质量)。这项研究的目的是探讨在RRT开始时经液体平衡调整后的肌酐是否与28天死亡率相关,而与AKI的其他指标,肌肉质量和疾病严重程度无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号